Business / Finance

RSS

ICICI Lombard General Insurance Company launches new ad campaign

Insurance is all about a 'Promise'. A promise that needs to be fulfilled during the hour of need. This is a unique category where the value of the product is realised not at the time of purchase but sometime in future when an unfortunate event/accident occurs for which the insurance cover was purchased. It is this 'moment of truth' that separates one insurance company from the other in terms of whether or not a claim is settled and the speed of settlement thus adequately compensating the insured for the loss.

20 Feb 2013

iCAD fourth quarter total revenue increases 18% to $7.8 million

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.

19 Feb 2013

Solta Medical fourth quarter revenue increases 20% to $39.8 million

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced results for the fourth quarter ended December 31, 2012. Revenue for the fourth quarter was $39.8 million, an increase of $6.6 million, or 20%, as compared to the fourth quarter of 2011.

19 Feb 2013

Oncolytics Biotech to commence underwritten public offering of common shares

Oncolytics Biotech Inc. announced today its intention, subject to market and other conditions, to commence an underwritten public offering of common shares. The number of common shares to be distributed and the price of each common share will be determined in the context of the market with final terms to be determined at the time of pricing.

19 Feb 2013

BioCryst fourth quarter revenues decrease to $4.1 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2012.

19 Feb 2013

NeuroMetrix fourth quarter total revenues decrease to $1.5 million

NeuroMetrix, Inc., a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported business and financial highlights for the quarter and twelve months ended December 31, 2012.

19 Feb 2013

Government of Québec announces $10M investment in Personalized Medicine Partnership for Cancer

The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC).

16 Feb 2013

LifePoint Hospitals fourth quarter revenues increase 14.3% to $893.3 million

LifePoint Hospitals, Inc. today announced results for the fourth quarter and year ended December 31, 2012.

15 Feb 2013

Shengtai second quarter net sales increase 49.31% to $64,103,621

Shengtai Pharmaceutical, Inc., a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the three months ended December 31, 2012.

15 Feb 2013

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patient's immune system to seek out and attack cancerous cells and tumors.

15 Feb 2013

Cardinal Health announces plans to acquire AssuraMed

Cardinal Health today announced plans to acquire privately held AssuraMed, a leading provider of medical supplies to patients in the home, for $2.07 billion, or $1.94 billion, net of the present value of tax benefits.

15 Feb 2013

AccentHealth purchases Everwell waiting room television network

AccentHealth, the nation's largest media network at the Point-of-Care, announced today it has purchased the Everwell waiting room television network, a division of MediVista Media, LLC.

15 Feb 2013

Masimo's total fourth quarter revenue increases 18% to $132.2 million

Masimo today announced its financial results for the fourth quarter and year ended December 29, 2012.

15 Feb 2013

Ingenuity Systems receives HIPAA Certification

Ingenuity Systems, a leading provider of biomedical information and analysis solutions, today announced that it has passed the Health Insurance Portability and Accountability Act (HIPAA) audit, confirming that Ingenuity's data center and Ingenuity Variant Analysis are in compliance with relevant Federal Regulations.

15 Feb 2013

National Mentor Holdings first quarter revenues increase 7.5% to $294.9 million

National Mentor Holdings, Inc. today announced its financial results for the first quarter ended December 31, 2012.

15 Feb 2013

SQI Diagnostics reports net loss of $1,563,000 for quarter-ended December 31, 2012

SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the first quarter-ended December 31, 2012.

15 Feb 2013

Health care staff can use QPID's intelligence engine to gain better insights from EHRs

QPID Inc. launched today, delivering a new health record intelligence platform and web-based applications that enable health care institutions and clinicians to gain better insights from any Electronic Health Record (EHR).

15 Feb 2013

SunLink second quarter consolidated net revenues decrease 4.0% to $27,850,000

SunLink Health Systems, Inc. today announced net earnings for its second fiscal quarter ended December 31, 2012 of $3,935,000, or $0.42 per fully diluted share, compared to a net loss of $935,000, or a loss of $0.10 per fully diluted share, for the quarter ended December 31, 2011.

14 Feb 2013

Innophos reports net sales of $209 million for fourth quarter 2012

Innophos Holdings, Inc., a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets, today announced its financial results for the fourth quarter and full year 2012.

14 Feb 2013

Regeneron fourth quarter total revenues increase to $415 million

Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

14 Feb 2013